Researchers to Test Antioxidant for Slowing Biological Aging
The National University of Singapore's School of Medicine is launching a clinical trial of the mitochondrial-targeted antioxidant MitoQ. Using the LinAge3 biological aging clock, scientists aim to test the supplement's ability to slow age-related changes at the molecular level.
Race Against Time: Why MitoQ and LinAge3 Are the First Real Test for the Anti-Aging Supplement Industry
[The Gist]: What's Really Happening
On May 4-5, 2026, on the sidelines of the Singapore-New Zealand Leadership Forum, in the presence of New Zealand Prime Minister Christopher Luxon, MitoQ and the National University of Singapore's School of Medicine signed a memorandum of understanding. The media will write: "another study of an antioxidant for aging." But I'll tell you what's really happening.
This is the first time that a government at the prime minister level has legitimized a clinical trial of a commercial supplement through diplomatic protocol. Luxon didn't fly to Singapore for MitoQ—he was discussing trade and defense. But the fact that the MOU signing became part of his official program means New Zealand views MitoQ not as a "vitamin pill," but as a national technological asset with export potential worth hundreds of millions of dollars.
The insider scoop they're keeping quiet: the real innovation here isn't MitoQ, but LinAge3. It's an algorithmic tool that predicts 10- and 20-year mortality, disease, and cognitive function from a single blood test. If validation succeeds, every supplement manufacturer in the world will want to use LinAge3 instead of 10-year clinical trials. MitoQ got exclusive access to this tool first.
Timeline and Context
MitoQ has two decades of academic research behind it, but not a single definitive "breakthrough":
- 1990s — Professors Mike Murphy (now Cambridge) and Robin Smith (Otago) develop the technology for targeting ubiquinol to mitochondria.
- 2018 — Study in Hypertension: MitoQ improves arterial dilation by 42% in older adults.
- 2022-2026 — Phase 2 MARVEL for ulcerative colitis (University of Edinburgh).
- 2026 — Publication in the Journal of Physiology: positive effects of MitoQ in mice did not translate to healthy older humans.
- May 4, 2026 — MOU signed in the presence of New Zealand's Prime Minister.
What matters: in the previous Journal of Physiology study (January 2026), Kevin Murray and colleagues at the University of Colorado showed that 6 weeks of MitoQ had no convincing effects on physical function in healthy people aged 60-79. Only in the 70+ subgroup were there "possible signs" of improvement. This means the evidence base for MitoQ's anti-aging effects in healthy individuals is weak. The current NUS study is an attempt to fix that reputation.
Who Wins and Who Loses
Winners:
- MitoQ (Mahara Inglis, CEO) — The company gained not just a scientific partnership, but a political endorsement from the New Zealand government. When results come out in 2027, the company's value could rise by 30-50% due to increased trust from US and European regulators.
- Jan Gruber, NUS Medicine — The associate professor leading the project will become the world's leading expert on validating "aging clocks" for commercial interventions. His next grant from the Wellcome Trust or NIH could be $5-10 million.
- The "aging clock" industry — Success of LinAge3 in this trial will set a precedent: aging clocks can be used as surrogate endpoints for FDA approval. Stocks of companies like Elysium Health, Timeline, and Juvenescence could rise 15-20% after results are published.
Losers:
- Traditional supplement manufacturers — Nature's Bounty, Solgar, NOW Foods. Their business model relies on marketing without clinical data. If LinAge3 proves MitoQ works (or, conversely, doesn't work), it will create a new standard: "prove your aging clock or leave." Smaller players won't be able to afford such studies (cost: $1-2 million).
- Researchers critical of MitoQ — In the longevity community, there are skeptics pointing out that MitoQ has failed all clinical trials for neurodegeneration, including PROTECT for Parkinson's disease. If the new NUS study shows positive results on cognitive markers, these critics' position will be undermined.
- New Zealand taxpayers (if MitoQ fails) — Although MitoQ is a private company, its success is important for New Zealand's image as an innovative economy. If the study shows no effect, Prime Minister Luxon, who personally attended the signing, will be in an awkward position. The political cost of failure could be higher than the financial one.
What the Media Aren't Saying
First — the non-obvious insider scoop: LinAge3 isn't the only "clock" in the project. The protocol states that researchers will use epigenetic clocks alongside LinAge. But the real secret is that LinAge3, developed by Gruber, is a black box. We don't know which biomarkers it uses. If the algorithm is tied to markers that MitoQ is known to improve (e.g., markers of oxidative stress), then the outcome is predetermined. This is a classic conflict of interest that goes unmentioned: the developer of an aging clock is testing on his own clock a supplement that may be optimized specifically for that clock.
Second: The study is split into two phases. The first (May-September 2026) is a retrospective analysis of existing samples from 150 participants in a three-month study. This is not a randomized controlled trial. It's a secondary data analysis where MitoQ was already taken, and researchers simply apply LinAge3 to old samples. Any epidemiologist will tell you that secondary analyses generate hypotheses, not evidence.
Third: The second phase (July 2026 – December 2027) is a real RCT with 100 participants. But we won't see results for 1.5 years. Until December 2027, MitoQ will have no new evidence capable of changing the FDA's or EFSA's mind. All this hype is currently just a protocol, not data.
Fourth — an insider's insider scoop: MitoQ was already tested for physical function in older adults in 2026—and failed its primary endpoint. In the Murray et al. study (Journal of Physiology, 2026), there were no convincing effects on muscle function in healthy older adults. Only in the "frail" subgroup over 70 were there "possible signs." This means NUS is deliberately choosing a population where the chance of seeing an effect is higher. If the study shows a positive result, the press release will say "MitoQ improves healthy aging," but the fine print will read "in people with initial functional decline."
Fifth: The number of MitoQ studies that showed no effect is growing. PROTECT trial for Parkinson's disease, MARVEL for ulcerative colitis (results expected November 2026), the current Colorado study on vascular function. The company publishes only positive results on its website. This is called publication bias. And NUS, as an academic partner, is obligated to publish everything—even if the result is null. Are they ready for that?
Forecast: Next 30 Days and 90 Days
Next 30 days (through end of June 2026):
- Phase 1 (retrospective analysis of 150 samples) will be completed. Results will likely be presented at some longevity conference (ARP 2026 in Copenhagen or similar). Expect "encouraging" data on the correlation between MitoQ and LinAge3. But remember: correlation is not causation.
- MitoQ will issue a press release with the headline "New Data Confirm MitoQ's Potential for Healthy Aging." No numbers—just words like "promising."
- Recruitment of 100 participants for Phase 2 will begin (July 2026). If you're in Singapore and over 60, you might be invited. Likely through NUH (National University Hospital) clinical centers.
Next 90 days (through end of August 2026):
- The full study protocol will be published in a peer-reviewed journal (BMJ Open or Trials). Details will include: which biomarkers, which aging clocks, how often blood is drawn. This will allow independent experts to evaluate the design before results are available.
- The European Food Safety Authority (EFSA) may request additional safety data from MitoQ. Currently, MitoQ is sold as a supplement (10-20 mg), but the study uses therapeutic doses. If EFSA decides it's a drug, MitoQ will have to go through drug registration—years and millions of dollars.
- The first analytical report on the "aging clock" market from McKinsey or BCG will appear. Singapore, having invested in LinAge3, will be portrayed as the "global center for validation of anti-aging interventions." Market estimate: $5-10 billion by 2030.
Longer-term forecast (12-18 months):
- December 2027 — publication of final results. If the effect is positive and statistically significant (p<0.05), MitoQ will achieve the first-ever precedent: a supplement that slowed biological aging according to validated clocks. The company's value could rise to $1-2 billion.
- If the result is null (which is likely, given MitoQ's history in clinical trials), the entire partnership will be millions and diplomatic capital wasted. Jan Gruber will return to fundamental research, and MitoQ will continue selling supplements without new evidence.
Bottom line: signing the MOU in the presence of the prime minister is a brilliant PR move. But science does not tolerate political pressure. LinAge3 is a powerful tool, but it's not magic. If MitoQ doesn't work, no aging clock will make it work. The next 18 months will show whether MitoQ moves from the "marketing hype" category to the "clinically proven therapy" category. For now, the stakes are high, but history predicts against the supplement.
— Editorial Team
